Health care stocks were decreasing late Wednesday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) easing 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.4%.
In sector news, US Secretary of Health and Human Services Robert Kennedy Jr. is weighing a proposal for a key government vaccine advisory panel to scrutinize vaccines with aluminum ingredients, Bloomberg reported. A review could impact at least two dozen vaccines, the report said.
In corporate news, Zoetis (ZTS) shares were falling 3.7% after Stifel downgraded the stock to hold from buy and cut its price target to $160 from $165.
Gilead Sciences (GILD) shares added 0.3% after the drugmaker said the US Food and Drug Administration has approved its Yeztugo, its twice-yearly injectable for HIV prevention.
Caris Life Sciences (CAI) shares surged 23% in their Nasdaq debut Wednesday after the company priced its IPO of 23.5 million shares at $21 each.
Grail (GRAL) shares jumped 13% after the firm said it has seen better cancer detection results from an analysis of the first 25,578 participants in its Pathfinder 2 study, compared with the previous Pathfinder study.
Maia Biotechnology (MAIA) shares popped 9% after the company said it has signed a clinical master supply agreement with Roche
for hard-to-treat cancer therapies.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。